A series of novel N1-amino-acid substituted 2,4,5-triphenyl imidazoline derivatives was designed and synthesized based on our previous studies. All synthesized target compounds were screened for their p53-MDM2 binding inhibitory activities and anti-proliferative activities against five cancer cell lines. Among them, twelve compounds displayed improved binding inhibitory activities and most compounds showed higher cell growth inhibition activities with IC(50) values in the low micromolar range. Compound 6c exhibited marked p53-MDM2 binding inhibitory activity (IC(50)=0.59 μM) which was eightfold more potent than that of Nutlin-1 (IC(50)=4.78 μM). CoMFA analysis was performed based on obtained biological data and resulted in a statistically significant CoMFA model with high predict abilities (q(2)=0.645, r(2)=0.979).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2012.01.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modulating the p53-MDM2 pathway: the therapeutic potential of natural compounds in cancer treatment.
EXCLI J
November 2024
Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43B, 07100 Sassari, Italy.
The p53-MDM2 pathway plays a crucial role regulating tumor suppression and is a focal point of cancer research. This literature review delves into the complex interplay between the tumor suppressor protein p53 and its main regulator MDM2, highlighting their interaction and implications in cancer development and progression. The review compiles and summarizes the existing understanding of the biology and regulation of p53 and MDM2, emphasizing their roles in various cellular processes, including cell cycle regulation, DNA repair, apoptosis, and metabolism.
View Article and Find Full Text PDFFLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia.
Cancer Lett
January 2025
Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China. Electronic address:
Article Synopsis
- FLT3 mutations are common in AML, making them a key target for therapy, but resistance to FLT3 inhibitors is a significant challenge.
- Tyrosine kinase inhibitors (TKIs) promote p53 degradation in FLT3-ITD AML cells through mechanisms involving STAT5 and MDM2, disrupting p53's role as a tumor suppressor.
- Using MDM2 inhibitors alongside TKIs can stabilize p53 levels, enhancing the effectiveness of treatments and suggesting a promising combination approach for AML therapy.
Illudin S inhibits p53-Mdm2 interaction for anticancer efficacy in colorectal cancer.
Biomed Pharmacother
January 2025
Department of Chemistry, Sungkyunkwan University, Suwon 16419, Republic of Korea. Electronic address:
The impairment of the p53 pathway was once regarded as inadequately druggable due to the specificity of the p53 structure, its flat surface lacking an ideal drug-binding site, and the difficulty in reinstating p53 function. However, renewed interest in p53-based therapies has emerged, with promising approaches targeting p53 and ongoing clinical trials investigating p53-based treatments across various cancers. Despite significant progress in p53-targeted therapies, challenges persist in identifying effective therapeutic targets within the p53 pathway.
View Article and Find Full Text PDFActivation of the Snail transcription factor induces Mdm2 gene expression.
J Biol Chem
November 2024
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, Indiana, USA; Department of Biochemistry and Molecular Biology, Indiana University, Indianapolis, Indiana, USA. Electronic address:
Epithelial-like tumor cells can become metastatic by undergoing molecular and phenotypic reprogramming in a process referred to as epithelial-to-mesenchymal transition (EMT). In response to EMT genes that promote migration and condition the tumor microenvironment to permit intravasation into the bloodstream, dissemination and extravasation into new organs are induced. While the mutant p53 has been implicated in extravasation, one negative regulator of p53, the oncogene murine double minute-2 gene (Mdm2), is required in the early stages of metastasis and the driver of EMT.
View Article and Find Full Text PDFDesign, Synthesis, and Biological Evaluation of Lysine-Stapled Peptide Inhibitors of p53-MDM2/MDMX Interactions with Potent Antitumor Activity .
J Med Chem
October 2024
Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, Chongqing 401331, People's Republic of China.
We introduce novel lysine-stapled peptide inhibitors targeting -MDM2/MDMX interactions. Leveraging the model peptides pDI (LTFEHYWAQLTS) and PMI-M3 (LTFLEYWAQLMQ) as starting points, a series of lysine-stapled analogues were designed and synthesized. Through cell assay screening, two lead compounds, SPDI-48-T and SPMI-48-T, were identified for their excellent antiproliferation activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!